SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-279632
Filing Date
2019-10-31
Accepted
2019-10-31 07:39:09
Documents
15
Period of Report
2019-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d827411d8k.htm   iXBRL 8-K 27645
2 EX-99.1 d827411dex991.htm EX-99.1 53240
6 GRAPHIC g827411img1.jpg GRAPHIC 30766
7 GRAPHIC g827411img2.jpg GRAPHIC 5961
  Complete submission text file 0001193125-19-279632.txt   261902

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20191031.xsd EX-101.SCH 3065
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20191031_lab.xml EX-101.LAB 18140
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20191031_pre.xml EX-101.PRE 11405
14 EXTRACTED XBRL INSTANCE DOCUMENT d827411d8k_htm.xml XML 3359
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 191182126
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences